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INTRODUCTION AND REVIEW OF THE LITERATURE 
One of the major problems in cancer chemotherapy is 
the nonselective action of the antiproliferative agents used. 
The fact that nonmalignant as well as cancerous cells are 
affected results in severe toxicity problems. and therefore, 
chemotherapeutic agents in general cannot be used in dosages 
sufficient to destroy every neoplastic cell, a condition 
necessary for a true "cure If (Mihich. 1970). 
Immunotherapy, on the other hand, has not been notably 
successful as a sole means of treatment of detectable malig-
nancy, probably because the tumor cells, by this time. have 
achieved numbers far above that which antibody-forming cells 
can kill by themselves (Fass and Fefer, 1972). Nevertheless. 
there is the obvious advantage of the highly specific nature 
of the immune response (Klein, 1966) whereby antibodies can 
be made against new tumor-cell antigens. These antibodies 
would not react with normal cells that lack these antigens. 
Recent approaches to this problem combine sublethal 
chemotherapy with immunotherapy (Fass and Fefer, 1972) in an 
attempt to compensate for the weaknesses of each system; 
adequately reducing tumor size by means of an appropriate 
chemical agent. then eradicating any remaining cells by 
existing immune mechanisms or by immunotherapy (Mihich, 1970). 
Friend Virus Disease is a leukemia of the erythroid-
myeloid series (Metcalf et al. p 1959) induced by a virus 
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accidentally discovered by Charlotte Friend in the course of 
examining the Ehrlich ascites tumor (Friend. 1957). The 
virus itself is an ether-sensitive RNA virus which has been 
extensively described in electron-microscopic studies 
(deHarven and Friend, 1958, 1960a). The particle appears as 
two concentric shells, each a double membrane about 50 j 
thick. The outer shell measures 87 mp and the inner 52 mp. 
The virus material is usually denser between the outer and 
inner membranes as compared to that in the central portion. 
giving the particle the doughnut shape characteristic of 
Type A virus particles. Such particles are frequently 
observed in a budding sequence, particularly in the mega-
karyocytes, both at the plasma membrane and in vacuoles 
within the cytoplasm. Particles also are seen in intimate 
contact with cell membranes of leukemic cells and budding 
from these membranes which form an envelope or peplos respon-
sible for the ether sensitivity characteristic of the particle 
(Friend, 1957). Chan et ala (1968) similarly report virus 
particles in close association with cell membranes in the 
spleen. 
In her original report, Friend (1957) also determined 
the physical stability of the viral agent. noting that 
filtrates of infected spleens were active after storage at 
-70°C for 6 months. at 4°C for 11 days. and when lyophilized 
for) months. Infectivity was destroyed by heating at 56°c 
for )0 minutes, by overnight exposure to ether at 4°c and by 
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treatment with a 11200 dilution of formalin. 
The disease itself centers in the hemopoietic tissue 
of the spleen and liver, causing marked splenomegaly and 
hepatomegaly. with death often resulting from splenic rup-
ture. In addition, Friend (1957) described large mononuclear 
cells with rounded, lobed, or horseshoe-shaped nuclei, pre-
sent in the peripheral blood. Metcalf et all (1959) have 
termed these "Friend Cells tl and include them with lymphocytes 
in classifying the hematology of the disease. Other patho-
logical features include anemia, lymphocytosis, thrombocy-
topenia and many red blood cell abnormalities. 
These same authors note that the first histological 
signs of the disease are observed in the spleen as early as 
four days after infection, when enlargement of reticulum 
cell foci is visible in the subcapsular area, along splenic 
trabeculae, and in the pulp spaces between lymphoid follicles. 
Numerous erythroblasts in various stages of development are 
noted around these foci and later, similar foci are observed 
in the liver. 
Siegler and Rich (1965) propose that splenic enlarge-
ment is due to intense proliferation of erythrocyte precur-
sors in the red pulp of the spleen. and that the failure of 
these cells to mature results in the anemia characteristic 
of the disease. This view is supported by tissue culture 
studies (Patuleia and Friend, 1967) showing that cultures 
of undifferentiated reticulum-cell sarcoma derived from 
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spleen or liver cells of Friend virus-infected animals 
eventually mature to proerythroblasts. The view of Boiron 
et ale (1965) that the so-called "Friend cell" is probably a 
proerythroblast further corroborates the erythroblastic 
nature of Friend disease, as does the work of Reilly and 
Schloss (1971) which proposed that erythrocytes of infected 
animals are carriers of the Friend virus particle. 
Metoalf et ale (1959) note that a progressive lympho-
cytosis occurs the second day after infection and reaches 
levels of 15,000 - 30,000 / CU mIll in 7 - 14 days. This. 
along with the findings of Ceglowski and Friedman (1969 and 
1970) that the immunosuppressive effect of Friend virus-
induced leukemia is based on interference with the maturation 
of lymphoid precursor cells suggests that the lymphoid cell 
line is involved in the disease. 
In addition, the myeloid series is postulated as a 
possible target site for Friend virus replication in the 
work of Thomson (1969). He found that bone marrow, contain-
ing more myelocytes than lymphocytes, was better able to 
transmit Friend disease to lethally irradiated animals than 
was splenic tissue, containing more lymphocytes than 
granulocytes. Finally, megakaryocytes have been observed 
(deHarven and Friend~ 1960b) as sites of viral budding, 
although these cells are not leukemic. Brodsky et ale (1968) 
propose, however, that this results in increased platelet 
fragility and consequent thrombocytopenia. 
Much of the above evidence strongly suggests that 
Friend virus multiplies in pluripotential stem cells of the 
hemopoietic series. More recently, the work of Jacoby 
(1972) with Friend disease and leucogenenol proposes that 
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the synergism between the virus and the molecule is attribut-
able to the fact that leucogenenol stimulates proliferation 
of the very stem cells in which Friend virus replicates. 
A final aspect of Friend disease to be considered is 
its immunosuppressive effect (Salaman and Wedderburn, 1966). 
In electron microscope studies, few nonnal. recognizable 
plasma cells or lymphocytes can be found in the spleens of 
Friend Virus-infected animals (Chan et al., 1968) and they 
propose that the immunologic defect caused by the virus may 
result from competition between antigens and virus particles 
for specific stem cells. This same view is reiterated by 
Ceglowski and Friedman (1970) who indicate a quantitative 
deficiency in the number of antibody-forming cells in spleens 
and livers of leukemic mice. Since once the immune mechanism 
has been stimulated by antigen, virus infection has only a 
slight effect. it seems logical that the immunosuppressive 
effect of Friend virus occurs in primitive, immunocompetent 
cells rather than at the level of the small, committed 
lymphocyte (Koo et al., 1971). 
Such considerations directed the attention of Jacoby 
(1972) and this investigator to leucogenenol. This compound 
was found by Rice and Ciavarra (1971) to stimulate the 
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maturation rate of antibody-producing cells and consequently 
to elicit normal antibody titers in splenectomized animals. 
Leucogenenol was first isolated by Rice (1966) from 
Penicillium gilmanii and later by Rice and Shaikh (1970) from 
normal bovine and human liver. Chemical analysis (Rice, 
1971) indicated that the comp~und is an enol of the formula 
C18H25N08 and is 2-(1,2, dihydroxy-3-methyl-5-oxocyclohexyl) 
-),11, dihydroxyl-11-(hydroxymethyl)-9-methyl-1-oxa-5-
azaspiro ~,5Jundeca-2t4 dien-7-one. The molecule is of 
interest because of its ability to induce leucocytosis with-
out a febrile response when injected into rabbits (Rice, 
1966). In a later study, the same author (Rice, 1968) 
demonstrated that in mice the injection of leucogenenol 
stimulates marked lymphocytosis with a corresponding drop in 
neutrophils four hours after injection. Studies of the 
effect of leucogenenol on the cells of the bone marrow of 
mice (Rice and Darden, 1968) indicate an increase in myelo-
blasts after 24 hours followed by a return to normal levels 
at the end of 5 days. At the same time an apparent decrease 
in lymphocytes and lymphoblasts occurs. The transitory 
nature of this neutrophilia as well as the fact that neutro-
phil increase is followed by a decrease in promyeloblasts 
and myelocytes at the end of 48 hours indicates that leuco-
genenol acts by increasing the rate of production of one 
cell type from another. leading to the formation of the 
mature neutrophil. The lymphoid decrease is followed within 
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48 hours by a sharp increase in the number of lymphocyte.s 
(Rice, Lepick and Darden, 1968), indicating that leucogenenol 
stirnula tes the rna turation and/or cell division of both mye-
loid and lymphoid cells. This conclusion is further sup-
ported by the finding that an increase in peripheral blood 
lymphocytes occurs in irradiated mice given leucogenenol and 
that spleen imprints from the same animals reveal a twofold 
increase in the relative number of lymphoblasts 24, 48 and 
120 hours after injection. 
Further studies on irradiated mice (Rice, Lepick and 
Hepner, 1970) demonstrate more rapidly arising and increased 
hemolysin titers in animals treated with leucogenenol as com-
pared to those untreated. Since lymphoid cells are known 
producers of antibody it is again suggested that the com-
pound increases the rate at which these cells recover from the 
effects of X-radiation damage. A more recent study (Rice et 
al., 1972) notes that injection of leucogenenol together with 
sheep erythrocytes into splenectomized rats results in the 
formation of normal titers of 19S (IgM) hemolysin. The 
authors suggest that leucogenenol acts by increasing the 
rate of transformation of immunoincompetent cells into 
antigen-reactive lymphocytes. 
Autoradiographic studies of the action of leucogenenol 
on the blood cells of the rat (Rice, McCurdy and Aziz, 1971) 
whereby tritiated thymidine was injected concurrently with 
leucogenenol. demonstrate that the most intense label is 
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found in the proliferating pool of cells in the bone marrow 
and is then transferred to cells in the myeloid series. 
Likewise, spleen imprints show a signi:ficant increase in the 
percentage of labeled lymphocytes following leucogenenol 
injection. In the same study, it is suggested that although 
leucogenenol does not appear to have any striking action of 
erythroid cells, the significant increase in labeled pro-
rubricytes 12 and 24 hours after administration of leuco-
genenol may suggest that the compound stimUlates the matura-
tion of at least one type of nucleated erythroid cell. 
More extensive autoradiographic studies in rats (Rice, 
Connolly, Aziz and McCurdy, 1971) attribute the decrease in 
peripheral neutrophils 12 hours after injection to an effi-
cient sequestering mechanism in the animal, a proposal sup-
ported by the concomitant increase in labeled neutrophils in 
the spleen. The same study points out that the lymphocytosis 
occurring after injection of leucogenenol is accompanied by 
an even greater increase in labeled lymphocytes, indicating 
increased maturation of lymphoid precursors, a finding which 
is in agreement with the previously noted suggestion that 
leucogenenol increases the rate of transformation of antibody-
producing cells (Rice et al., 1972). 
Finally, studies on the action of leucogenenol on 
lymphoblastoid cells of normal and neoplastic origin propose 
that leucoffenenol somehow affects the enzyme systems that are 
Co 
associated with the transformation of cells (Rice and fVicCurdy, 
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1971). Further, Rice, Blum and Rene (1970) suggest that the 
fact that leucogenenol is a normal constituent of liver tis-
sue implies that it may playa role in the normal growth and 
regulation of hemopoietic cells. 
It is thus strongly suggested that leucogenenol is 
instrumental in regulating the proliferation and transforma-
tion of stem cells. possibly the same cells in which Friend 
virus is presumed to replicate. These findings were suppor-
tive of those of Jacoby (1972) who, working with the inter-
action of Friend virus disease and leucogenenol, found that 
the compound potentiates the leukemia, probably by providing 
more sites in which the virus can replicate; more cells which 
can be transformed by it. At the same time, however, leuco-
genenol evidently does counteract the immunosuppressive 
effect of Friend disease. as evidenced by the production of 
near normal antibody titers in infected animals treated with 
leucogenenol. Nevertheless, it is proposed that these 
normal antibody levels are inefficient against massive levels 
of both viral particles and tumor cells. 
It is possible that the beneficial aspects of leuco-
genenol might be better exploited if an appropriate course 
of chemotherapy were first administered in an attempt to 
reduce the number of neoplastic cells. Thus t the folic acid 
antagonist Illethotrexate was chosen as an antiproliferative 
agent in these experiments. 
The basis for an understanding of the action of 
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Methotrexate lies in the role of folic acid (pterylglutamic 
acid), a compound isolated in the 1940's and associated with 
hemopoietic activity as evidenced by its therapeutic effect 
on some anemias (Pfiffner et al., 1947). The experimental 
use of folic acid antagonists demonstrated a competition 
between the antagonist and folic acid resulting in a general 
slowing of growth, reduction in the percentage of hemoglobin 
and a reduced leucocyte count (Franklin~ al., 1947). This 
work suggested that since folic acid antagonists evidently 
depress cytopoietic mechanisms they may be useful in treating 
diseases of erythrocytosis or leucocytosis-
Farber et ale (1948) rather successfully employed 
aminopterin. a closely related predecessor of Methotrexate 
(amethopterin) in the treatment of leukemia in children. The 
synthesis of a methylated analogue of aminopterin followed 
that of aminopterin and its effects on experimental animals 
were studied (Seeger et ale, 1947). Inhibition of growth, 
anemia, leucopenia and granulocytopenia were noted by 
Franklin et ale (1949), who also suggested that the compound 
might be used as a chemotherapeutic agent in the treatment of 
myelogenous leukemia. Such experiments were conducted and 
Methotrexate was shown to prolong the survival time of mice 
infected with leukemia AK4 (Burchenal et al., 1949). The 
observation that reduced folic acid compounds blocked the 
effect of Methotrexate led to the suggestion that its mode 
of action involved blocking the biochemical reduction of 
11 
folic acid to tetrahydrofolic acid (Jukes. 1953). In work 
with leukemic mice, Balis and Dancis (1955) note that 
thymidilic acid biosynthesis is the reaction most sensitive 
to the action of folic acid antagonists. 
'.Phe enzyme system needed for the reduction of folic 
acid was obtained in partially purified form from chicken 
1 i vers by Futterman (1957), who also demonstrated that 
aminopterin blocked the action of the reductase. In the fol-
lowing year amethopterin (Methotrexate) was shown to have the 
same blocking effect (Osborn et al., 1958). These authors 
state that the primary site of action is probably only at the 
step which reduces dihydrofolic acid to tetrahydrofolic acid. 
Peters and Greenberg (1959) found that the enzyme. as 
extracted from sheep liver. could be titrated with aminopterin, 
a finding which is explained by the fact that the binding of 
the drug to the enzyme is so strong that the dissociation 
constant is quite small (Werkheiser, 1961). The close 
similarity between the structure of folic acid and that of 
Methotrexate further supports this mechanism. Folic acidl 
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Methotrexate: 
?N, /N~ 
H2 j\I-C C C-H CH 3 C-c 0 COOH I ! I I I II \\ I I ,/ 
N" C C H N-C C-C CH 
"yl " /' 'C/ \ - I .... N/ 'CH -CH -COOH 
NH2. N H C -C H 2 2 
Holland (1961) notes that the inactivation of folic 
reductase by folic antagonists disrupts the capacity for 
cell multiplication by interfering with nucleic acid bio-
synthesis, thereby producing the clinical signs of leucopenia, 
thrombocytopenia and erythrocytopenia; symptoms associated 
with tissues noted for fairly rapid proliferation. Delmonte 
and Jukes (19(52) propose that the effects of Methotrexate 
are due to the blocking of the enzyme dihydrofolic reductase, 
and thereby interfering with the production of tetrahydro-
folic acid, a compound which, after several intermediate 
reactions, transfers carbon atoms to deoxyuridilic acid to 
form thymidilic acid, a component of DNA (Jukes, 1961). 
Werkheiser (1963) also notes that a lesser inhibition of 
purine synthesis has been found. Thus, the lethal action of 
Methotrexate is likely to be on cells that are in rapid DNA 
synthesis (Blackett, 1968) and more specifically on those 
in the S-phase of the generation cycle (Bruce et ale, 1966). 
Borsa and Whitmore (1969) further note that although cells 
outside the S-phase are not killed, their progression through 
the cell cycle may be prevented by the inhibition of purine 
synthesis. The same study points out that if purines are 
added to the culture medium, thereby inhibiting thymidilic 
acid synthesis only. cells in the G, M, and G2 phase lose 
their viability when they reach the S phase. 
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Thus, it is rather surprising that Methotrexate has 
not been notably successful in the therapy of Friend disease. 
Mirand et ala (1961) observed that the drug caused a signi-
ficant decrease in spleen size and decreases in Fe.59 uptake, 
by the spleen but no increase in survival time. Along simi-
lar lines, Chirigos et ala (1965) report the same decreases 
in spleen size induced by methotrexate, but no decrease in 
virus recovery from infected animals. 
Methotrexate also acts as an immunosuppressive agent 
(Uphoff, 1958). In studies with guinea pigs it was shown 
that animals sensitized with Bacille Calmette-Guerin (BeG) 
then given Methotrexate, failed to develop positive skin 
tests, although viable lymph node cells from these animals 
were able to transfer tuberculin hypersensitivity (Friedman 
and Bucy...ler. 1963). If animals were treated with Methotrex-
ate after being given such sensitized cells, hypersensitivity 
failed to develop until the drug was discontinued. The con-
clusion was reached that Methotrexate selectively inhibited 
the proliferation of immunologically active cells. This 
conclusion is further supported by a reversal in differential 
white cell counts (Friedman, 1964). In Methotrexate-treated 
guinea pigs, the counts were 66~0 polymorphonuclear neu trophils 
(PMN's) and 34% lymphocytes, whereas in untreated animals 
the proportion was 38% PMN's and 62% lymphocytes. Both 
groups had also received BCG. 
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Thus, some problems arise regarding the use of Metho-
trexate in Friend disease therapy. An important question is 
why the drug seemingly does not prolong the survival time of 
infected animals. Mirand et ale (1961) suggests tha t the 
parameters of spleen weight and Fe59 uptake are more sensi-
tive indicators of drug effect than mortality, and Chirigos 
et ale (1965) proposes that the intensity of viremia was 
simply too great for the drug to be effective. Another 
possibility might be the toxicity of the compound, which 
could result in the early death of the animals. Further, 
the immunosuppressive effect of Methotrexate may also be an 
important factor in the failure of the drug to prolong sur-
vival time. 
Bacille-Calmette Guerin (BCG) is an attenuated strain 
of Mycobacterium bovis accidentally discovered in 1906 by 
Calmette and Guerin as they were culturing the virulent 
parent strain on glycerine-bile-potato medium. (Calmette 
and Guerin, 1906). During the1920's BCG was used pro-
phylactically in young infants in the United states, although 
considerable controversy surrounded its use. Today, BeG is 
used extensively throughout the world except in the United 
States as a means of immunization against tuberculosis. 
'rhe observation that survivors of tuberculosis were 
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less susceptible to neoplastic growth led several investiga-
tors to the experimental use of BCG therapy in conjunction 
with malignant growths. Old et al .. (1959) injected BCG into 
mice, then inoculated the animals with several types of 
transplantable tumors. The tumors grew normally for the 
first 8 to 10 days, then 70 - 75% of them regressed. An in-
crease in spleen weight accompanied by multiple large 
granulomas implicates reticula-endothelial involvement as a 
possible mechanism (Old et al., 1961). Weiss et al. (1961) 
found both living BeG as well as phenol-killed, acetone-
extracted and methanol-extracted organisms to be effective 
when given before tumor transplants. Retardation in onset 
of tumor development, prevention of tumor development. slowing 
of tumor growth, regression of tumor, inhibition of metas-
tasis and increase in life span were some notable effects. 
Many varying hypotheses have been advanced to explain 
the mechanism of action of BCG, but very few conclusions have 
been reached. Lemonde and Clade (1962) suggest that increased 
phagocytic activity and an increased antibody response are 
responsible for increasing survival time in leukemic mice. 
They also postulate that the mild inflammatory disturbance 
caused by BOG infection may increase the secretion of hor-
mones such as the corticosteroids which may inhibit neo-
plasms. Studies with skin graft rejection led to the observa-
tion that BCG infection results in a greater number of func-
tionally altered phagocytic cells and exerts a proliferative 
stimulus on cells of the reticuloendothelial system, which 
in turn may cause more vigorous production of immunocompe-
tent cells (Old et al., 1961). 
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Skin graft studies were also employed by Vitale and 
Allegretti (1963) who also implicate the reticuloendothelial 
system in BOG-induced reactions. It also has been noted 
that BOG infection in mice increases the total number of 
nucleated spleen cells as well as the number of plaque-
forming cells as tested with sheep erythrocytes (Stjernsward, 
1966). He further suggests that since BOG can increase the 
number of antibody-producing cells to an unrelated antigen. 
its effect might be due to nonspecific proliferation of stem 
cells. Another possibility is that increased phagocytosis 
and therefore increased uptake of antigen may lead to more 
immunologically competent cellS. Lemonde and Clode (1966) 
propose that protection results not from antibodies directed 
against the virus but possibly from those against antigens 
induced in cells made neoplastic by the virus, i.e., tumor 
antigens. This view is supported by studies involving 
Adenovirus type 12 inoculated into mice which were given BCG 
4 weeks later (Sjogren and Ankerst. 1969). These authors 
propose that BOG immunity involves nonspecific transplanta-
tion antigens, since BCG was given at a relatively late stage 
oftha latent period when an antiviral immune response would 
no longer be possible. A study of cellular kinetics by 
North (1969) shows that BeG infection resulted in intense 
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proliferation of lymphoid cells in the spleen andprolifera-
tion of macrophages in the peritoneal cavity. 
Zbar et ale (1970) inoculated tumor cells mixed with 
BCG into guinea pigs and noted an inflammatory response to 
BeG but no tumor growth. The animals were immune to further 
challenge by tumor cells of the same type. A delayed 
cutaneous hypersensitivity to the tumor cells was noted. 
Continued work with guinea pigs points to a possible mechanism 
of delayed hypersensitivity (Zbar and Tanaka, 1971). Further, 
actual contact between BCG and tumor cells is proposed as 
necessary for participation of the host's immune defenses 
(Zbar et al., 1971). Such participation is deemed essential 
since guinea pigs with impaired defenses are unable to sup-
press tumor growth even in the presence of BCG. 
Considerable confUsion arises in the literature of 
the past few years regarding the nature of the response to 
BCG. Schwartz et ale (1971) suggest that BCG initiates a 
local immunological response which alters the oncogenicity 
of the virus in the area, but state that the mechanism for 
this is not known. Along the same line of thought. Lemonde 
et ale (1971) found that in mice and hamsters given BGG, 
antibody titers to polyoma virus increased, suggesting that 
BGG stimUlates tumor immunity, evidently of a humoral nature. 
This position is contradicted by Reif and Kim (1971) who 
found that BCG did not stimUlate primary antibody responses 
to sheep erythrocytes and suggest that cellular rather than 
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humoral responses are involved. Likewise, the finding that 
sera from patients with growing tumors could block the cyto-
toxic effect of lymphocytes immune to those tumors, implies 
that cellular rather than humoral responses are of benefit 
in tumor immunity (Hellstrom et ala t 1971). Further support 
is offered by Sokal et ale (1972) who, upon injection of BCG 
and cultured cells into leukemia patients stimulated delayed 
hypersensitivity to the antigens of the target cells with 
little humoral antibody production. 
Further debate arises regarding the specific or non-
specific nature of the anti-tumor response induced by BOG. 
Working with mice, Bartlett et ale (1972) suggest that host, 
immune reactivity to BeG was necessary and possibly even 
sUfficient to prevent tumor growth at the site of BeG injec-
tion. Thus, tumor-specific immunity is not considered neces-
sary, but the tumor cells and the BCG must be in the same 
locale. The suggestion is made that tumor destruction may 
be due to nonspecific effects of specific reactivity to BCG. 
A possible mechanism in conjunction with this is suggested 
by Williams and Granger (1969) who propose that lymphocytes 
activated by antigen exposure may be nonspecifically cyto-
toxic. They note that cell destruction is initiated by 
lymphotoxins, perhaps in a nonspecific manner. Somewhat in 
contrast to this Pearson et ale (1972) suggest that BeG 
dramatically enhances a tumor-specific response in addition 
to activating nonspecific elements of the reticuloendothelial 
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system. 
More recent studies describe a granulomatous histio-
cytic reaction at the tumor site and in the draining lymph 
nodes after BOG infection (Hanna et al., 1972). These authors 
raise the question of whether this reaction might be classi-
fied with delayed hypersensitivity in the realm of cellular 
immunity, pointing out that while granUlomatous inflammation 
is often a major characteristic of antimicrobial cellular 
immunity, histiocytes do accumUlate in delayed-type anti-
tissue reactions. It is suggested that the histiocytes may 
be necessary for the more predominant lymphocytic reaction in 
antitissue immunity, and that lymphocyte sensitization may 
occur during the granUlomatous reaction. Thus, there are 
many speCUlations and few conclusions regarding the mechanism 
of BCG action on tumors, save a tentative one that the pro-
cess of tumor destruction is immunologically nonspecific. 
Finally, BCG has been shown to be effective therapy 
against Friend disease. Larson et ale (1970) administered 
BGG before Friend virus and noted that the mortality rate 
among treated animals was significantly less. In a later 
study (Larson et al., 1972) BCG was given 1 or 3 weeks after 
Friend virus. Spleen weights were significantly lower, 
fewer foci were present in the spleens, and life spans were 
lengthened in BCG-treated mice. 
This study represents an attempt to retard the progres-
sion of Friend virus disease in BALB/C mice, employing 
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Methotrexate chemotherapy as a means of reducing the popula-
tion of tumor cells, and leucogenenol and BCG immunotherapy 
as a means of stimulating the animals' own immune responses 
to the tumor cells. 
METHODS AND MATERIALS 
Young adult female BALB/c mice, weighing about 20 g 
were obtained from Simonsen Laboratories, Gilroy, Calif. and 
from Cumberland View Farms, Clinton, Tenn. They were kept 
in disposable plastic cages in groups of no more than 10. 
sterilized sawdust bedding was used. The mice were given 
water and standard laboratory chow ad libitum. 
Friend Virus 
The Friend Virus was obtained from the stock pool 
maintained in our laboratory. The history of this stock 
has been described by Elliott et ale (1970) and by Elliott 
and Schloss (1971). The ID50 was 104/002 ml given intra-
peritoneally. A 10-3 dilution was made as follows, After 
removal from -700 C storage, the virus stock was thawed by 
gentle swirling in a 37°0 water bath. About 2 ml of the 
suspension were transferred to a sterile centrifuge tube 
and spun for 10 minutes at 2000 XG. A 10-1 dilution. then 
a 10-3 dilution of the supernatant were made using millipore-
filtered sucrose stabilizer (ETIiott et alo. 1970). Dilutions 
were made at a temperature close to OOC maintained by ice. 
In all experiments, 0.2 ml of 10-3 virus dilution were in-
jected intraperitoneally. 
Leucogenenol 
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Leucogenenol was isolated from lyophilized bovine 
liver (Nutritional Biochemicals Corporation, Cleveland, Ohio) 
according to the procedure of Rice and Shaikh (1970) as modi-
fied by Jacoby (1972). In all experiments, 0.4 llg dissolved 
in 0.2 ml sterile. pyrogen-free water were injected intra-
peritoneally. 
Methotrexate 
Methotrexate was obtained in powdered form from 
Nutritional Biochemicals Corporation. Cleveland, Ohio. This 
was dissolved in a sterile 4% solution of NaHCO J prepared in 
pyrogen-gree water and given in a dose of 2.5 mg/kg sub-
eu taneously (Floersheim. 1970). 
Bacille Calmette-Guerine (BCG) was obtained as a 
frozen suspension from Trudeau Institute, Inc., Saranac Lake, 
New York. through the courtesy of Dr. G. P. Kubica. It was 
kept at -70oC until use. This suspension was diluted with 
.15M sterile saline and administered intraperitoneally in a 
dose of 4.0 x 106 viable units in 0.2 mI. 
Experimental. Design 
A total of 67 mice were divided into 8 groups. The 
groups varied in size because certain animals had been 
infected with parasites and had to be eliminated from the 
experiment. The groups were treated as follows: 
Group 1. Untreated Control group. 8 mice. 
Group 2. Control group; injected with Friend Virus 
only. 8 mice. 
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Group 31 Inoculated with Friend Virus. Leucogenenol 
administered 12 and 19 days after infection. 
9 mice. 
Group 4. Inoculated with Friend Virus. BeG adminis-
tered 14 days after infection. 9 mice. 
Group 5 f Inocula ted with Friend Virus. Nlethotrexa te 
given on three consecutive days beginning 
7 days after infection. 8 mice. 
Group 6 & Inocula ted with Friend Virus. rv;ethotrexa te 
given on three consecutive days beginning 
7 days after infection. Leucogenenol given 
12 and 19 days after infection. 11 mice. 
Group 71 Inoculated with Friend Virus. Methotrexate 
given on three consecutive days beginning 
7 days after infection. BeG administered 
14 days after infection. 9 mice. 
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Group 8t Inoculated with Friend Virus. Methotrexate 
given on three consecutive days beginning 
7 days after infection. Leucogenenol given 
12 and 19 days after infection. BeG 
administered 14 days after infection. 5 
mice. 
The animals were checked several times each day to 
remove dead mice. The dates of the animals' deaths were 
recorded. At death, each mouse was weighed and autopsied. 
The spleen and liver were excised and also weighed, and the 
ratios of the weights computed. 
Differential blood counts were made 2, 4, and 6 weeks 
after infection. Peripheral blood samples were obtained 
from tail snips and the smears were stained with Wright's 
stain and examined at 1000X. A total of 100 cells were counted 
and classified. Questionable cells were examined by several 
qualified people. 
Statistical analysis was conducted by a standard 
t-test, comparing various animal groups. The p values were 
then determined from a standard table. In general, signi-
ficance was ascribed to a p value of < 0.10. In several 
instances, values extremely close to 0.10 are reported as 
> 0.10. 
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RESULTS 
In Table 1 and. Figure 1, there was no difference in 
survival time between FV-infected animals which were treated 
with either leucogenenol or BeG and those that were left 
untreated (p not significant). In.fected animals treated 
solely with Methotrexate (MTX) did show a significant in-
crease (p < .05) in lifespan over those infected but not 
treated. Animals treated with both MTX and leucogenenol 
also had a substantially longer lifespan (p ) .1) than un-
treated animals. The same was true for animals treated with 
IvI'FJC and BGG (p ) .. 1).. Treatment with MTX t leucogenenol and 
BGG si§,71ificantly prolonged the life of infected animals as 
compared to infected but untreated controls to approximately 
the same extent as did treatment with MTX alone. 
Treatment with MTX and leucogenenol resulted in a 
significantly longer lifespan (p <.1) than did treatment 
with leucogenenol only. Treatment with both MTX and BOG 
resulted in a slightly but nonsignificantly longer lifespan 
than did treatment with BCG alone. No significant differ-
ences in survival time were noted when leucogenenol was 
added to MTX treatment, when BCG was 8.dded to MTX treatment 
or when both leucogenenol and BeG were added to MTX treat-
ment. Also, no significant difference was found when BeG 
was added to treatment with M'rX and leucogenenol, nor when 
MTX and leucogenenol were added to treatment with BCG. Nor 
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rrable 1. M~an sur:rival tim~ in days of BALB/c mice injected 
w1th var10US comb1nations of FV, leucogenenol. 
Methotrexate (MTX) and BeG. 
GROUP 
MEAN SURVIVAL 
TIME (days) 
1 No treatment Terminated - 146 
2 FV only 46.63 
3 FV + Leucogenenol 43·70 
4 FV + BeG 46·50 
5 FV + MTX 56.25 
6 FV + MTX + Leucogenenol 57· 27 
7 FV + fijTX + BeG 51 · 78 
8 FV + MTX + BCG 
+ Leucogenenol 55·00 
RANGE 
(days) 
----- (8)* 
40-62 (8) 
39-47 (9) 
35-61 (9) 
39-72 (8) 
38-96 (11) 
43-55 (9) 
53-59 (5) 
* Number in narentheses represents the number of mice used 
in calculating each value. 
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Figure 1. Mean survival time in days of BALB/c mice 
injected with various combinations of FV, 
leucogenenol. Methotrexate (MTX) and BCG. 
Untreated controls not included. 
Group 21 FV only 
Group 3. FV + Leucogenenol 
GriHlJ;ljO' 4J. FY. +. BE£t 
Group 5 I FV + MTX 
Group 61 FV + MTX + Leucogenenol 
Group 7, FV + MTX + BCG 
Group 81 FV + MTX + BCG + Leucogenenol 
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was a significant difference observed between animals treated 
with MTX and BCG and those treated with lVITX, BCG, and leuco-
genenol. 
The greatest significant difference in lifespan 
(p < .001) was observed between infected animals given only 
leucogenenol and those infected mice treated with MTX, leuco-
genenol and BOG, the latter having the longer survival time. 
No significant differences were observed in spleen 
and liver/total body weight ratios in any of the groups 
except that the ratio for all FY-infected animals, no matter 
what subsequent treatment, if any, was given, was much 
grea ter than that of normal, noninfected mice (p <.001). 
These data can be found in Table 2 and Figure 2. 
Table 3 and Figure 3 show the data comparing the per-
centages of lymphocytes among the various treatment groups 
at different times in the experiment. Treatment with 
leucogenenol as compared with lack of such treatment in the 
control animals significantly raised the percentage of 
lymphocytes in week 2 (p < .025) but not in week 4 or 6 
(p not significant). In contrast, treatment with BeG alone 
did not result in any significant difference in lymphocytes 
between this group and untreated controls. As compared to 
untreated but infected controls. animals treated with NITX 
alone showed a significant drop in the number of lymphocytes 
at weeks 2 (p < .005), 4 (p < .005) and 6 (p <. .05) as did 
animals treated with IVlTX and leucogenenol (p < .005. p < .05 
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Table 2. Average ratios of spleen and liver weight to total 
body.wei¥ht of BALB/c mice injected with various 
co,mbl.natl.ons of FV t leucogenenol, Methotrexate (IvlTX) and BCG. 
GROUP 
1 No treatment 
2 FV only 
3 FV + Leucogenenol 
4 FV + BGG 
5 FV + MTX 
6 FV + J'.1TX + Leucogenenol 
7 FV + M TX + BC G 
8 FV + l'fiTX + BCG 
+ Leucogenenol 
AVERAGE 
SPLEEN + LIVER WT. 
TOTAL BODY WEIGHT 
0.063 
0.287 
0·302 
0.)15 
0.295 
0.)06 
0.)25 
0.)07 
RANGE 
.057-.071 (8)* 
.248-.320 (5) 
.280-.340 (6) 
.2lf)-.415 (5) 
.217-·354 (7) 
.249-.)87 (8) 
.255-.)67 (8) 
.276-.3)3 (5) 
* Number in parentheses represents the number of animals 
used in computing ratios. Some animals could not be used 
because of ruptured spleens. 
Figure 2. Average ratios of spleen and liver weight to 
total body weight of BAtB/e mice injected with 
various combinations of FV. leucogenenol, 
Methotrexate (MTX) and BCG. 
Group 1. Untreated controls 
Group 2. FV only 
Group JI FV + Leucogenenol 
Group 4. FV + BeG 
Group 5. FV + flITX 
Group 6t FV + MTX + Leucogenenol 
Group 7 t FV + MTX + BCG 
Group 8. FV + MTX + BCG + Leucogenenol 
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Table 3. Average percentage of lymphocytes in peripheral 
blood smears of BALB/c mice injected with various 
combinations of FV , leucogenenol, Methotrexate (MTX) and BCG. 
GROUP 
1 No treatment 
2 FV only 
3 FV + Leucogenenol 
4 FV + BeG 
5 FV + MTX 
6 FV + MTX + Leucogenenol 
7 FV + MTX + BeG 
8 FV + fv'ITX + BeG 
+ Leucogenenol 
WEEK 2 WEEK 4 WEEK 6 
% LYMPHS ~ LYMPHS % LYMPHS 
65.6 (9) 71.7 (8) 71.3 (8)+ 
77.5 (8) 83.8 (8) 80.0 (5) 
84.4 (9) 87·3 (9) 82.0 (4) 
78.1 (9) 8).4 (5) 73 oJ (6) 
63.) (8) 75.1 (8) 71.) (7) 
67.3 (11) 79.8 (11) 73.5 (10) 
75.7 (5) 68.2 (5) 71.6 (5) 
'* Number in parentheses represents the number of slides 
used in computing the mean. 
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and p <.10). Significant decreases in the percentage of 
lymphocytes were also found in animals treated with MTX and 
leucogenenol as compared with those treated with leucogenenol 
alone in weeks 2 (p < .001) and 4 (p < .005). However. a 
significant rise in the percentage of lymphocytes occurred in 
week 4 (p < .05) and slight but nonsignificant increases took 
place in weeks 2 and 6 when leucogenenol was added to MTX 
therapy. 
Animals that received MTX and BCG showed a significant 
drop in the percentage of lymphocytes over those not treated 
at all sampling times (p <.005. p <.005 and p < .01). 
Adding BCG to treatment with MTX, however, produced no signi-
ficant differences in the percentage of lymphocytes, but 
adding BeG to treatment with MTX and leucogenenol produced a 
significant drop in week 4 (p < .001). Also, adding BCG and 
leucogenenol to treatment with MTX produced a drop in the 
percentage of lymphocytes in week 4 (p <: .05). There was no 
significant difference in week 6. Animals treated with MTX 
and BCG showed a significant drop in the percentage of 
lymphocytes in weeks 2 (p < .01) and 4 (p < .005) when com-
pared to mice treated with BCG only, but adding both leuco-
genenol and MTX to BeG treatment produced a significant drop 
only in week 4 (p <.005). Mice treated with MTX and BCG in 
addition to leucogenenol showed significant drops in the per-
centage of lymphocytes as compared with animals given only 
leucogenenol in weeks 2 and 4 (p <.001 and p <.1). Adding 
2 
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leucogenenol to MTX and BOG treatment produced a signif'icant 
rise in the percentage of lymphocytes in week 2 (p <.1) but 
no significant differences in weeks 4 and 6. 
DISCUSSION 
Methotrexate was significantly effective in prolonging 
survival time of FV infected mice. This is in marked con-
trast with the report of' Mirand et ala (1961) and may be 
accounted for by several factors. Mirand used HA/IeR Swiss 
mice rather than the BALB/c animals used here. and he admin-
istered MTX in a different dosage and time schedule, employ-
ing smaller doses of 1 mg/kg Over a longer period of 11 days, 
beginning 24 hours after FV infection. In this experiment, 
a dose of 2.5 mg/kg was given for :3 consecutive days beginning 
7 days after infection. Also. a dif'ferent strain of FV was 
employed. Mirand (1966) uses a polycythemic strain whereas 
the strain used in these experiments is anemia-producing. 
All of these differences are important factors in judging 
the effectiveness of MTX treatment of Friend Virus Disease. 
The beneficial effect of MTX in these experiments is 
not surprising from a biochemical point of view. Since the 
compound prevents the formation of thymidilic acid by com-
peting with folic acid for the reductase (Delmonte and Jukes, 
1962), it should be expected to be detrimental to any rapidly 
diViding cells, including those of Friend Virus Disease. 
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Further, since Mirand et a1. (1961) report that the compound 
did have some effect on certain parameters of the disease, 
such as spleen weight and Fe59 uptake. the results reported 
here simply seem to extend those findings. 
In all cases in these experiments. animals treated 
with MTX had significantly longer lifespans than those not 
so treated. Since the known molecular action of the drug is 
the blockage of DNA synthesis by preventing thymine formation 
(Delmonte and Jukes, 1962), it can be said that the drug's 
main effect is probably due to the destruction of the rapidly 
proliferating tumor cells. MTX also acts to prevent the 
development of T-lymphocytes which are active in ce11-
mediated immune responses to neoplastic cells (Friedman and 
Buckler, 1963). Thus it is noted that all animals that 
received MTX treatment in these experiments exhibited signi-
ficantly lower percentages of lymphocytes in peripheral 
blood. Since the suppression of T-1yrnphocytes is extremely 
detrimental in the treatment of leukemia, it seems that the 
beneficial effect of MTX in destroying tumor cells outweighs 
the destruction of T-Iymphocytes. at least under the condi-
tions described for these experiments. 
BeG alone had no effect on either survival time or on 
the percentage of lymphocytes in the peripheral blood. 'This 
is in direct contradiction to results obtained by Larson at 
al. (1970 and 1972). In his first experiments wi th BeG and 
FV, the author immunized mice with BeG before infecting them 
• 
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with FV. This seems to be an artificial situation since a 
disease cannot be treated before it is present. In the 
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later experiments, BOG was given either 1 or 3 weeks after 
infection by the intravenous route. The size of the BOG 
inoculum was the same as that used here, but further compari-
sons are impossible since Larson does not mention the strain 
of mice or BOG used nor does he describe the history of the 
FV pool employed. The results reported here are, perhaps, 
more in agreement with the work of Hanna, Zbar and Rapp 
(1972) in which tumor regression was noted when BOG was 
injected directly into the tumor site. They explained the 
beneficial results of BOG therapy as consisting primarily of 
a localized granUlomatous inflammatory reaction. Since 
Friend Virus Disease is not localized but systemic and 
infiltrates a great variety of tissues, it is not so sur-
prising that BeG showed little effect since a granulomatous 
inflammation simply cannot occur in all the organs and areas 
which FV infiltrates. 
Further, adding BeG to MTX therapy had no appreciable 
beneficial effect. It is postulated that the T-lymphocytes 
were so suppressed by the drug that BeG stimUlation was 
ineffective in restoring their ability to develop reactivity, 
thus decreasing the destructive effect that these cells 
would have upon any tumor cells present. Likewise, treat-
ment with leucogenenol. another immunostimulant, had no 
effect after the administration of MTX. Perhaps here too, 
-
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lv.'TX so efficiently suppressed immunocompetent cells that 
stimulation was impossible. Also. it is known that leuco-
genenol stimulates the production of humoral antibodies 
(B-cells) but it is not yet known what effect, if any, the 
drug has on T-lymphocytes. If the compound does, in fact, 
stimulate only B-cells. no beneficial results could be ex-
pected since tumor rejection is mediated by cell-bound anti-
bodies produced by T-cells and blocked by humoral antibodies 
produced by B-cells. As with BGG, however, the possibility 
exists that IVITX suppressed both tumor cells and T-lymphocytes 
to the extent that stimulation by leucogenenol was simply 
not enough to restore the production of the cytotoxic anti-
tumor T-lymphocytes. Along the same lines, these present 
experiments suggest that even immunostimulation with both 
BeG and leucogenenol was not sufficient to restimulate the 
T-cells suppressed by MTX. 
'Ehe effects of MTX. however, were not permanent and 
after treatment was discontinued some evidence of "over-
shoot" (Pfeiffer and Tolrnack, 1967) was present as increased 
but non-significant spleen-liver ratios. hven though JvITX 
was effective in reducing tumor cell population in the 
beginning, as the drug was eliminated and newly synthesized 
folic acid reductase was not being blocked by the MTX. the 
remaining cells were again able to proliferate rapidly. 
Also, at this time there was less hindrance from T-lymphocytes 
since their development had been suppressed by the drug and 
= 
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a longer period of time is required for their maturation. as 
well as for the development of the lymphotoxic effect of 
these T-cells. Thus, the progression of the disease was 
temporarily slowed by MTX treatment as shown by increased 
survival time, but the spleen-liver ratios did not show this 
effect since measurements were taken at the time of death 
from leukemia rather than at a time of maximum drug inhibi-
tion. In essence, when animals are given even effective 
drug treatment but the treatment is then stopped, the pro-
gression of the disease continues in the same manner as it 
would without treatment, although lifespan is increased. 
This is further supported by the data showing that in almost 
every case the beneficial effect of chemotherapy and immuno-
therapy on the percentage of lymphocytes in the peripheral 
blood had disappeared by the sixth week. 
Although the slight drop in survival time as well as 
the elevation of spleen-liver ratios produced by leucogenenol 
were not significantly different from those of FV-infected but 
untreated animals, there was a definite and significant in-
crease in the percentage of peripheral lymphocytes indicating 
that the drug did have an effect on these cells. Since it 
is known that leucogenenol stimulates the proliferation of 
cells producing humoral antibodies, or B-lymphocytes (Rice. 
Lepick and Hepner, 1970) it can be postulated that leucogenenol 
simply may provide more replication sites for the virus. This 
data supports the conclusions of Jacoby (1972 ) and also 
-
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explains why the addition of leucogenenol to iVlTX treatment 
had no beneficial effect in these experiments. The immuno-
suppressive effect of FV due to virus invasion of B-cells 
cannot be overcome by treatment with leucogenenol, even 
though the drug does stimulate antibody production in non-
infected animals, since the cells resulting from leucogenenol 
stimulation will be transformed by the virus and the whole FV 
leukemic process proceeds more rapidly in the presence of 
elevated numbers of viruses (Fieldsteel et al., 1961). 
It would be of value to repeat these experiments with 
several important modifications. First. some animals should 
be terminated after administering a complete course of drug 
and immunotherapy and spleen-liver ratios determined at that 
time should be compared with those of untreated animals. It 
would be expected that these weights would be significantly 
lower than those of untreated animals. Secondly, a second or 
even third course of drug and immunotherapy should be given 
after the animals had a SUfficient time to allow for recovery 
from any toxic drug effects. In this way, newly proliferating 
tumor cells would be destroyed several times and the antibody 
producing ability of these animals would have been enhanced 
several times. with multiple drug and immunotherapy there 
perhaps would be a statistically significant increase in life 
span as compared to animals treated only once. 
Furthermore, leucogenenol needs to be tested further 
in a localized tumor system which does not directly involve 
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the hemopoietic system. It is suggested that perhaps in 
such a system stimulation of elevated antibody titers would 
have a significantly beneficial effect in the destruction of 
tumor cells. 
SUMlVIARY 
These experiments were designed to investigate whether 
the immunostimulants leucogenenol and BeG when added to 
Methotrexate chemotherapy could retard the progression of 
Friend Virus Disease. Although Methotrexate therapy did 
prolong survival time, cessation of treatment was followed 
by evidence of normal progression of the leUkemia and thus, 
at death, there were no significant differences in spleen-
liver weight ratios when treated animals were compared to 
untreated controls. The data also indicate that MTX decreased 
the percentage of lymphocytes in the peripheral blood during 
the course of its administration. Treatment with immuno-
stimulants had no appreciable effect on the progress of the 
disease. It is therefore concluded that the effect of 
I.'lethotrexa te therapy was to suppress the production and 
sensitization of T-lymphocytes so efficiently that consequent 
attempts at immuniblogical restimulation were ineffective. 
Furthermore, this suppression was sufficiently great so that 
upon cessation of Methotrexate therapy the proliferation of 
leukemic cells exceeded that of new immunocompetent T-lympho-
cytes. 
-
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